Evaluating Kylo-11 for Long-Acting Lipoprotein(a) Suppression
Steven Nissen, MD, and Ashish Sarraju, MD, discuss early clinical data on Kylo-11, a novel therapy that produced substantial reductions in lipoprotein(a) for up to one year after a single injection. Lowering lipoprotein(a), a genetically determined cardiovascular risk factor linked to atherosclerotic disease and aortic stenosis, remains an important focus for preventive cardiology. Learn about the new drug's mechanism and safety findings. Lookin…